Bevacizumab biosimilar - Shandong Boan Biotechnology

Drug Profile

Bevacizumab biosimilar - Shandong Boan Biotechnology

Alternative Names: LY 01008

Latest Information Update: 18 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Shandong Boan Biotechnology
  • Developer Luye Pharma Group; Shandong Boan Biotechnology
  • Class Antineoplastics; Eye disorder therapies; Monoclonal antibodies
  • Mechanism of Action Angiogenesis inhibitors; Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Colorectal cancer; Non-small cell lung cancer

Most Recent Events

  • 04 Aug 2017 Luye Pharma Group acquires bevacizumab biosimilar from Shandong Bo’an Biotechnology
  • 04 Aug 2017 Phase-I clinical trials in Colorectal cancer in China (Parenteral) before August 2017
  • 04 Aug 2017 Phase-I clinical trials in Non-small cell lung cancer in China (Parenteral) before August 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top